Project Management and CMO–Sponsor Relations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Project Management and CMO–Sponsor Relations
Using basic project management tools and ideas in the transfer process saves time and money and ensures high success rates.


Pharmaceutical Technology


CMOs must communicate issues early to their clients. If in the transfer process there are issues, do not try to solve those issues without good communication with the sponsor company or third-party laboratory. How often does a written method neglect the "art" part of the assay that can only be obtained through asking questions or trial and error?

Finally, and most importantly, ensure the timeline links method transfer with critical manufacturing dates. Demonstration runs and batches are to test quality-control processes and method usage and to validate the compounding and manufacturing processes. No one wants to be in the situation where the day before manufacturing the in-process test is not ready.

Quality is challenging. When thoughtfully considered and appropriately planned, however, it can actually be a pleasure. Many actually enjoy the laboratory. From a CMO scientist's perspective, nothing is more gratifying than valid results, successful filings, passing inspections, product release, and happy customers (CMOs, sponsor companies, and patients). These elements translate into excellent customer service.

Conclusion

Outsourcing with CMOs is a vital part of the pharmaceutical drug-manufacturing industry. Whether at the clinical-trial stage or the commercial production stage, sponsor company and CMO relationships are the basis for effective and timely regulatory filings and successful production.

As stated previously, it takes hard work, considerable organization, preparation, communication, and compromise to ensure the success of our projects. Companies using the principles reviewed here are those who will enjoy future success.

Sandra Lueken is a senior manager of quality control at Hollister Stier Laboratories, LLC, 3525 North Regal St., Spokane, WA 99207, tel. 509.482.0595, fax 509.484. 4320,
.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here